Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 2/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | CCND2 | P30279 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478984 | 0.87 | PTK2 (0.49) | SYKJAK2FGFR1PTK2JAK3 | |
| SCHEMBL12478994 | 0.84 | CCND3 (0.63) | SYKJAK2PTK2CCND3CCNK | |
| SCHEMBL17994178 | 0.80 | JAK2 (0.48) | SYKJAK2FGFR1PTK2JAK3 | |
| SCHEMBL14576658 | 0.80 | PTK2 (0.65) | PTK2 | |
| SCHEMBL14643156 | 0.80 | PTK2 (0.76) | PTK2 | |
| SCHEMBL30895328 | 0.80 | PTK2 (0.47) | SYKJAK2PTK2CDK2CDK4 | |
| SCHEMBL3820924 | 0.79 | CKS1B (0.53) | SYKCKS1BSKP1SKP2JAK3 | |
| SCHEMBL20459325 | 0.79 | PTK2 (0.61) | PTK2 | |
| SCHEMBL12478687 | 0.79 | PTK2 (0.47) | SYKJAK2FGFR1PTK2CKS1B | |
| Bromide SCHEMBL30895402 | 0.78 | PTK2 (0.46) | SYKPTK2CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| WO-2014027199-A1 | FAK AND FLT3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2014-02-20 | — | — | WO | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | SYK 10/4885JAK2 60/4885FGFR1 306/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | SYK 14/4885JAK2 81/4885FGFR1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.